338 related articles for article (PubMed ID: 18479171)
1. A review of the pharmacokinetics of abacavir.
Yuen GJ; Weller S; Pakes GE
Clin Pharmacokinet; 2008; 47(6):351-71. PubMed ID: 18479171
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study.
McDowell JA; Chittick GE; Ravitch JR; Polk RE; Kerkering TM; Stein DS
Antimicrob Agents Chemother; 1999 Dec; 43(12):2855-61. PubMed ID: 10582871
[TBL] [Abstract][Full Text] [Related]
3. Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
Moyle G; Boffito M; Fletcher C; Higgs C; Hay PE; Song IH; Lou Y; Yuen GJ; Min SS; Guerini EM
Antimicrob Agents Chemother; 2009 Apr; 53(4):1532-8. PubMed ID: 19188387
[TBL] [Abstract][Full Text] [Related]
4. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.
Wang LH; Chittick GE; McDowell JA
Antimicrob Agents Chemother; 1999 Jul; 43(7):1708-15. PubMed ID: 10390227
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
Musiime V; Kendall L; Bakeera-Kitaka S; Snowden WB; Odongo F; Thomason M; Musoke P; Adkison K; Burger D; Mugyenyi P; Kekitiinwa A; Gibb DM; Walker AS;
Antivir Ther; 2010; 15(8):1115-24. PubMed ID: 21149918
[TBL] [Abstract][Full Text] [Related]
6. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults.
McDowell JA; Lou Y; Symonds WS; Stein DS
Antimicrob Agents Chemother; 2000 Aug; 44(8):2061-7. PubMed ID: 10898676
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.
Crémieux AC; Katlama C; Gillotin C; Demarles D; Yuen GJ; Raffi F;
Pharmacotherapy; 2001 Apr; 21(4):424-30. PubMed ID: 11310515
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of lamivudine.
Johnson MA; Moore KH; Yuen GJ; Bye A; Pakes GE
Clin Pharmacokinet; 1999 Jan; 36(1):41-66. PubMed ID: 9989342
[TBL] [Abstract][Full Text] [Related]
9. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.
Yuen GJ; Lou Y; Thompson NF; Otto VR; Allsup TL; Mahony WB; Hutman HW
J Clin Pharmacol; 2001 Mar; 41(3):277-88. PubMed ID: 11269568
[TBL] [Abstract][Full Text] [Related]
10. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.
Kumar PN; Sweet DE; McDowell JA; Symonds W; Lou Y; Hetherington S; LaFon S
Antimicrob Agents Chemother; 1999 Mar; 43(3):603-8. PubMed ID: 10049274
[TBL] [Abstract][Full Text] [Related]
11. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.
Paediatric European Network for Treatment of AIDS (PENTA)
Antivir Ther; 2010; 15(3):297-305. PubMed ID: 20516550
[TBL] [Abstract][Full Text] [Related]
13. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.
Hughes W; McDowell JA; Shenep J; Flynn P; Kline MW; Yogev R; Symonds W; Lou Y; Hetherington S
Antimicrob Agents Chemother; 1999 Mar; 43(3):609-15. PubMed ID: 10049275
[TBL] [Abstract][Full Text] [Related]
14. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.
Hawkins T; Veikley W; St Claire RL; Guyer B; Clark N; Kearney BP
J Acquir Immune Defic Syndr; 2005 Aug; 39(4):406-11. PubMed ID: 16010161
[TBL] [Abstract][Full Text] [Related]
15. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Wit FW; Lange JM; Danner SA; Foudraine NA; Kwakkelstein MO; Reiss P; Beijnen JH; Hoetelmans RM
AIDS; 2000 May; 14(8):F77-82. PubMed ID: 10853971
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.
Jackson A; Moyle G; Dickinson L; Back D; Khoo S; Taylor J; Gedela K; Abongomera G; Gazzard B; Boffito M
Antivir Ther; 2012; 17(1):19-24. PubMed ID: 22267465
[TBL] [Abstract][Full Text] [Related]
17. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily.
Yuen GJ; Lou Y; Bumgarner NF; Bishop JP; Smith GA; Otto VR; Hoelscher DD
Antimicrob Agents Chemother; 2004 Jan; 48(1):176-82. PubMed ID: 14693537
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M
Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
[TBL] [Abstract][Full Text] [Related]
19. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
20. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.
Staszewski S; Katlama C; Harrer T; Massip P; Yeni P; Cutrell A; Tortell SM; Harrigan RP; Steel H; Lanier RE; Pearce G
AIDS; 1998 Nov; 12(16):F197-202. PubMed ID: 9833847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
